Written by Jane Aubrey
Leyden Laboratories has reported positive Phase 1 findings for RIG-101, an investigational intranasal innate-immune modulator intended to strengthen antiviral defenses in people vulnerable to respiratory viral disease. The September 9 company release says the candidate was safe and well tolerated in healthy volunteers and patients with asthma at tested dose levels for up to seven days of daily administration. It also reports an interferon and interferon-stimulated-gene response in the upper respiratory tract of asthma participants. Those are appropriate early signals for the proposed mechanism. They do not establish that RIG-101 prevents infections, asthma exacerbations, emergency visits or any other clinical outcome.
RIG-101 is designed to act on RIG-I, a mediator of innate antiviral immunity. The company’s hypothesis is that increasing local antiviral responses in the airway can help compensate for impaired natural defenses against respiratory viruses. That logic is appealing in asthma, where viral infections are associated with many severe exacerbations. Yet immune activation has a narrow therapeutic window. An intervention needs to be strong enough to trigger a useful antiviral response, targeted enough to do so where needed, and controlled enough to avoid unwanted local irritation or systemic inflammatory consequences. A Phase 1 program is designed to start resolving safety and pharmacodynamic questions, not to settle efficacy.
The reported biomarker outcome should be read in that light. Interferons and interferon-stimulated genes are biologically connected to the candidate’s intended antiviral mechanism. Observing them after intranasal dosing supports target engagement. It does not prove that the response is of the right magnitude, duration or timing to prevent a naturally occurring respiratory-virus event. Biomarkers can accelerate development by showing that a drug reaches and changes its intended pathway. Clinical benefit requires a second link in the chain: a reproducible association between that pathway change and outcomes patients experience.
Leyden Labs plans a human-rhinovirus challenge study in patients with asthma as the next Phase 2 step. That setting can be informative because it offers a more controlled way to assess viral exposure, symptoms, virologic measures and airway effects than an entirely naturalistic study. It will still need a disciplined endpoint strategy. Relevant measures may include virologically confirmed infection, exacerbation frequency or severity, symptom scores, lung function, rescue-medication use, healthcare utilization and the durability of any protection. The protocol should also account for background asthma therapy, prior viral exposure, baseline control and the heterogeneity of patients’ immune responses.
Safety evaluation will evolve as the exposed population expands. The announcement reports tolerability for up to seven days of dosing, which is useful but limited. Longer and larger studies will be needed to examine local nasal effects, systemic inflammatory signals, disease-specific responses and the balance between antiviral activation and airway sensitivity. The program’s intranasal route is strategically important: respiratory viruses enter through the mucosa, and local delivery may offer a way to act near the site of entry. It also means formulation, deposition, adherence and device use can influence clinical performance.
The asset came to Leyden Labs through its acquisition of RIGImmune earlier in 2026, along with the NEED intranasal delivery platform. The acquisition fits Leyden’s broader mucosal-protection approach, which also includes intranasal antibodies. Combining multiple modalities could diversify the pipeline, but it should not blur their evidence bases. An innate immune modulator, a broadly protective antibody and a vaccine each make different biological promises and face different safety, dosing and development challenges. RIG-101 should be judged on its own clinical evidence rather than on the appeal of a platform narrative.
The Phase 1 result justifies further study because the company reports both tolerability and a pharmacodynamic signal consistent with its mechanism. The key remaining question is practical: can that signal reduce clinically meaningful virus-triggered worsening in asthma without creating a trade-off in safety or burden? A well-designed challenge study can sharpen the answer, but confirmatory natural-exposure research will remain important. For now, RIG-101 is an early clinical program with an interesting airway-innate-immunity hypothesis—not a demonstrated preventive therapy.
This article is informational and educational only, not medical advice. Decisions about asthma care, infection prevention, or clinical-trial participation should be made with qualified clinicians using current, authoritative evidence and individual circumstances.
